Physician profile
Clement John
NPI 1184271074
$12,608.57
in general payments reported to CMS, 2019-2025
20 companies · $4,553 in 2025
The $4,553 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $1,886 · 2023: $2,726 · 2024: $2,895 · 2025: $4,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,768 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,767.62 |
| Education | $406.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,125.14 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,944.73 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,427.02 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,419.20 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,255.23 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,200.60 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,106.28 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $825.73 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $388.28 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $207.21 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $137.28 | 2023-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $124.33 | 2025 | Qelbree |
| Almatica Pharma LLC | $122.23 | 2024-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $104.83 | 2024-2025 | Auvelity |
| Indivior INC. | $72.51 | 2022-2024 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $63.40 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.53 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.75 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.99 | 2025 | |
| Noven Therapeutics, LLC | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.